Study Title
A Phase I Study to Assess Biodistribution of 89Zr-CB307 in PSMA+ and PSMA- Tumour Lesions (A Sub-study of CBT307-1 Study - EUDRACT 2019-004584-46)
Study Details
Description:
CB307 is a trispecific Humabody® targeting CD137; PSMA; and human serum albumin (HSA) undergoing Phase 1 assessment in patients with PSMA+ solid tumours. This sub study will assess the biodistribution of radiolabelled CB307 in patients with advanced and/or metastatic solid tumours that are PSMA+.
Sponsor:
Crescendo Biologics LtdContacts:
Julia Tilsonjtilson@crescendobiologics.com
07725 844778
Government Study Link:
NCT05836623 - Click here to see study onClinicalTrials.gov